Ingalls & Snyder LLC Omeros Corp Transaction History

Ingalls & Snyder LLC

$2.33 Billion
Q2 2024

A detailed history of Ingalls & Snyder LLC transactions in Omeros Corp stock. As of the latest transaction made, Ingalls & Snyder LLC holds 4,593,148 shares of OMER stock, worth $19.5 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares

4,593,148

Previous 4,698,140 2.23%

Holding current value

$19.5 Million

Previous $16.2 Million 15.05%

% of portfolio

0.8%

Previous 0.72%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$3.04 - $4.23 $319,175 - $444,116	-104,992 Reduced 2.23%	4,593,148 $18.6 Million
Q1 2024 May 13, 2024	BUY	$2.88 - $4.89 $435,968 - $740,238	151,378 Added 3.33%	4,698,140 $16.2 Million
Q4 2023 Jan 29, 2024	SELL	$1.08 - $3.63 $104,569 - $351,471	-96,824 Reduced 2.09%	4,546,762 $14.9 Million
Q3 2023 Nov 02, 2023	SELL	$2.81 - $5.69 $35,616 - $72,120	-12,675 Reduced 0.27%	4,643,586 $13.6 Million
Q2 2023 Jul 27, 2023	SELL	$4.45 - $7.57 $32,396 - $55,109	-7,280 Reduced 0.16%	4,656,261 $25.3 Million
Q1 2023 May 09, 2023	BUY	$2.48 - $5.22 $2.42 Million - $5.1 Million	976,800 Added 26.49%	4,663,541 $21.7 Million
Q4 2022 Jan 31, 2023	SELL	$1.75 - $3.96 $708,510 - $1.6 Million	-404,863 Reduced 9.89%	3,686,741 $8.33 Million
Q3 2022 Oct 21, 2022	SELL	$3.09 - $7.46 $182,798 - $441,318	-59,158 Reduced 1.43%	4,091,604 $12.9 Million
Q2 2022 Aug 11, 2022	SELL	$1.92 - $6.28 $104,309 - $341,179	-54,328 Reduced 1.29%	4,150,762 $11.4 Million
Q1 2022 May 09, 2022	SELL	$5.07 - $7.2 $598,954 - $850,586	-118,137 Reduced 2.73%	4,205,090 $25.3 Million
Q4 2021 Feb 11, 2022	SELL	$5.67 - $8.54 $789,774 - $1.19 Million	-139,290 Reduced 3.12%	4,323,227 $27.8 Million
Q3 2021 Oct 27, 2021	SELL	$13.4 - $16.3 $94,470 - $114,915	-7,050 Reduced 0.16%	4,462,517 $61.5 Million
Q2 2021 Aug 03, 2021	BUY	$14.81 - $19.13 $2.22 Million - $2.87 Million	149,775 Added 3.47%	4,469,567 $66.3 Million
Q1 2021 Apr 21, 2021	SELL	$14.52 - $23.53 $674,178 - $1.09 Million	-46,431 Reduced 1.06%	4,319,792 $76.9 Million
Q4 2020 Jan 27, 2021	SELL	$10.14 - $15.19 $473,588 - $709,448	-46,705 Reduced 1.06%	4,366,223 $62.4 Million
Q3 2020 Oct 21, 2020	SELL	$9.57 - $21.32 $235,804 - $525,324	-24,640 Reduced 0.56%	4,412,928 $44.6 Million
Q2 2020 Jul 31, 2020	SELL	$12.21 - $16.99 $2.43 Million - $3.38 Million	-198,737 Reduced 4.29%	4,437,568 $65.3 Million
Q1 2020 Apr 22, 2020	SELL	$9.03 - $19.72 $129,128 - $281,996	-14,300 Reduced 0.31%	4,636,305 $62 Million
Q4 2019 Jan 15, 2020	SELL	$13.01 - $17.15 $4.85 Million - $6.4 Million	-373,150 Reduced 7.43%	4,650,605 $65.5 Million
Q3 2019 Oct 16, 2019	BUY	$14.55 - $20.56 $846,780 - $1.2 Million	58,198 Added 1.17%	5,023,755 $82 Million
Q2 2019 Jul 11, 2019	SELL	$15.0 - $19.62 $1.68 Million - $2.19 Million	-111,700 Reduced 2.2%	4,965,557 $77.9 Million
Q1 2019 Apr 11, 2019	SELL	$11.65 - $17.72 $1.09 Million - $1.65 Million	-93,150 Reduced 1.8%	5,077,257 $88.2 Million
Q4 2018 Jan 24, 2019	SELL	$10.72 - $16.73 $991,921 - $1.55 Million	-92,530 Reduced 1.76%	5,170,407 $57.6 Million
Q3 2018 Oct 24, 2018	SELL	$17.73 - $26.69 $6.22 Million - $9.36 Million	-350,550 Reduced 6.24%	5,262,937 $128 Million
Q2 2018 Aug 10, 2018	BUY	$10.79 - $24.44 $762,043 - $1.73 Million	70,625 Added 1.27%	5,613,487 $102 Million
Q1 2018 Apr 17, 2018	BUY	$9.0 - $20.16 $1.87 Million - $4.19 Million	207,623 Added 3.89%	5,542,862 $61.9 Million
Q4 2017 Jan 19, 2018	BUY	$13.26 - $22.86 $2.31 Million - $3.98 Million	174,204 Added 3.38%	5,335,239 $104 Million
Q3 2017 Oct 20, 2017	BUY	$19.76 - $24.9 $102 Million - $129 Million	5,161,035	5,161,035 $112 Million

Others Institutions Holding OMER

# of Institutions

113

Shares Held

25.5M

Call Options Held

317K

Put Options Held

556K

View Full List

About OMEROS CORP

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $267M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

More about OMER

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.

Account

Ingalls & Snyder LLC Omeros Corp Transaction History